Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1Phase 1 1

Status

Completed 3Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Myeloid 3Other hematologic neoplasm 2

Conditions

Myelodysplastic Syndromes 3Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid, Acute 2

Interventions

Paclitaxel 489Carboplatin 435Gemcitabine 394Docetaxel 385Cisplatin 359pembrolizumab 343Bevacizumab 335Nivolumab 261Pemetrexed 242Capecitabine 221Dexamethasone 213Fluorouracil 211Rituximab 203Trastuzumab 193Cyclophosphamide 190Oxaliplatin 160Erlotinib Hydrochloride 147Ipilimumab 145atezolizumab 144Prednisone 144Cetuximab 142Irinotecan 139Leucovorin 130Doxorubicin 130Sorafenib 120Lenalidomide 119Bortezomib 118Sunitinib 107Everolimus 93130-nm albumin-bound paclitaxel 91

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × INDUSTRY × cedazuridine × Clear all
NCT02103478 2024-08-27

Pharmacokinetic Guided Dose Escalation and Dose Confirmation With Oral Decitabine and Oral Cytidine Deaminase Inhibitor (CDAi) in Patients With Myelodysplastic Syndromes (MDS)

Astex Pharmaceuticals, Inc.

Phase 1/2 Completed
130 enrolled 34 charts 1 FDA
Myeloid

Myelodysplastic Syndromes

NCT03306264 2024-08-27

Study of ASTX727 vs IV Decitabine in Participants With MDS, CMML, and AML

Astex Pharmaceuticals, Inc.

Phase 3 Completed
227 enrolled 37 charts 1 FDA
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT03813186 2024-08-02

Effect of Food on Blood Levels of ASTX727

Astex Pharmaceuticals, Inc.

Phase 1 Completed
18 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡